ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,749.00
0.35%
S&P ASX All Technology
3,067.50
0.14%
Brent Oil
82.585
0.00%
US Dollar vs AUD
1.50989
0.00%
Bitcoin
60,913.26
0.19%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Cingulate Inc (CINGW)

  7. Cingulate Inc (CINGW) News

CINGW

Cingulate (CINGW)

Cingulate Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CINGW
DateTimeSourceHeadlineSymbolCompany
08/05/202421:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CINGWCingulate Inc
08/05/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CINGWCingulate Inc
08/05/202421:00GlobeNewswire Inc.Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
30/04/202419:45GlobeNewswire Inc.Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live AccessNASDAQ:CINGWCingulate Inc
17/04/202407:00GlobeNewswire Inc.Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024NASDAQ:CINGWCingulate Inc
01/04/202423:00GlobeNewswire Inc.Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
20/03/202407:45GlobeNewswire Inc.Cingulate to Participate in Benzinga All Live Access EventNASDAQ:CINGWCingulate Inc
06/03/202422:45GlobeNewswire Inc.Cingulate to Attend DCAT Week 2024 in New York CityNASDAQ:CINGWCingulate Inc
13/02/202422:45GlobeNewswire Inc.Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of DirectorsNASDAQ:CINGWCingulate Inc
07/02/202408:15GlobeNewswire Inc.Cingulate Announces Closing of $7.5 Million Public OfferingNASDAQ:CINGWCingulate Inc
03/02/202401:15GlobeNewswire Inc.Cingulate Announces Pricing of $7.5 Million Public OfferingNASDAQ:CINGWCingulate Inc
30/01/202400:00GlobeNewswire Inc.Longtime Cingulate Controller Jennifer Callahan Promoted to CFONASDAQ:CINGWCingulate Inc
29/01/202422:45GlobeNewswire Inc.Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to MarketNASDAQ:CINGWCingulate Inc
02/12/202301:00GlobeNewswire Inc.Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)NASDAQ:CINGWCingulate Inc
14/11/202308:15GlobeNewswire Inc.Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
18/10/202305:22GlobeNewswire Inc.Cingulate to Host CNS Key Opinion Leader Panel in New York CityNASDAQ:CINGWCingulate Inc
22/09/202303:30GlobeNewswire Inc.Cingulate Inc. to Present at the LD Micro Main Event XVINASDAQ:CINGWCingulate Inc
14/09/202306:15GlobeNewswire Inc.Cingulate Announces Closing of $4.0 Million Public OfferingNASDAQ:CINGWCingulate Inc
11/09/202323:22GlobeNewswire Inc.Cingulate Announces Pricing of $4.0 Million Public OfferingNASDAQ:CINGWCingulate Inc
11/09/202320:00GlobeNewswire Inc.Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDNASDAQ:CINGWCingulate Inc
09/09/202306:31GlobeNewswire Inc.Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a PremiumNASDAQ:CINGWCingulate Inc
05/09/202322:00GlobeNewswire Inc.Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023NASDAQ:CINGWCingulate Inc
15/08/202306:15GlobeNewswire Inc.Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
11/07/202322:00GlobeNewswire Inc.Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDNASDAQ:CINGWCingulate Inc
29/06/202322:00GlobeNewswire Inc.Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and AugustNASDAQ:CINGWCingulate Inc
15/06/202305:45GlobeNewswire Inc.Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-VestNASDAQ:CINGWCingulate Inc
08/06/202321:00GlobeNewswire Inc.Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHDNASDAQ:CINGWCingulate Inc
26/05/202305:55GlobeNewswire Inc.Cingulate to Present at 13th Annual LD Micro InvitationalNASDAQ:CINGWCingulate Inc
13/05/202305:45GlobeNewswire Inc.Cingulate, Indegene to Participate in Benzinga All Live Access EventNASDAQ:CINGWCingulate Inc
11/05/202306:15GlobeNewswire Inc.Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:CINGWCingulate Inc
 Showing the most relevant articles for your search:NASDAQ:CINGW

Your Recent History

ASX
FLOT
VanEck Investments
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved